{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:40:02Z","timestamp":1790383202167,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jocn.2021.08.016","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T12:13:33Z","timestamp":1629720813000},"page":"153-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effect of bisphosphonates on ankylosing spondylitis: A meta-analysis"],"prefix":"10.1016","volume":"92","author":[{"given":"Il-Soo","family":"Eun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sik","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Min","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Sub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jocn.2021.08.016_b0005","doi-asserted-by":"crossref","first-page":"886","DOI":"10.31616\/asj.2020.0568","article-title":"Adult Spinal Deformity: Current Concepts and Decision-Making Strategies for Management","volume":"14","author":"Kim","year":"2020","journal-title":"Asian Spine J"},{"issue":"1","key":"10.1016\/j.jocn.2021.08.016_b0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4055\/cios.2020.12.1.107","article-title":"Correlation between Accelerometer and Questionnaire-Based Assessment of Physical Activity in Patients with Cerebral Palsy","volume":"12","author":"Kwon","year":"2020","journal-title":"Clin Orthop Surg"},{"key":"10.1016\/j.jocn.2021.08.016_b0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jocn.2016.01.020","article-title":"Perioperative complications in open versus percutaneous treatment of spinal fractures in patients with an ankylosed spine","volume":"30","author":"Moussallem","year":"2016","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2021.08.016_b0020","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jocn.2021.08.016_b0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00393-019-0654-3","article-title":"Neuropathic pain in ankylosing spondylitis: a meta-analysis","volume":"79","author":"Kim","year":"2020","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.jocn.2021.08.016_b0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/ard.2003.011247","article-title":"How to diagnose axial spondyloarthritis early","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jocn.2021.08.016_b0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MAJ.0b013e3182937335","article-title":"Ankylosing Spondylitis Clinical Registries: Principles, Practices and Possibilities","volume":"345","author":"Caplan","year":"2013","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.jocn.2021.08.016_b0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrrheum.2012.40","article-title":"Developments in therapies for spondyloarthritis","volume":"8","author":"Sieper","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jocn.2021.08.016_b0045","doi-asserted-by":"crossref","unstructured":"Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19:340-5.","DOI":"10.1097\/BOR.0b013e328133f57b"},{"issue":"3","key":"10.1016\/j.jocn.2021.08.016_b0050","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","article-title":"A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis","volume":"46","author":"Maksymowych","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jocn.2021.08.016_b0055","first-page":"144","article-title":"Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy","volume":"28","author":"Maksymowych","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jocn.2021.08.016_b0060","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jocn.2021.08.016_b0065","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.jocn.2021.08.016_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jocn.2021.08.016_b0075","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jocn.2021.08.016_b0080","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed","volume":"58","author":"Deeks","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jocn.2021.08.016_b0085","first-page":"445","article-title":"Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial","volume":"35","author":"Coates","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.jocn.2021.08.016_b0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jbspin.2010.05.010","article-title":"The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis","volume":"78","author":"Kang","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jocn.2021.08.016_b0095","doi-asserted-by":"crossref","unstructured":"Khabbazi A, Noshad H, Gafarzadeh S, et al. Alendronate effect on the prevention of bone loss in early stages of ankylosing spondylitis: a randomized, double-blind, placebo-controlled pilot study. Iran Red Crescent Med J. 2014;16:e18022.","DOI":"10.5812\/ircmj.18022"},{"key":"10.1016\/j.jocn.2021.08.016_b0100","doi-asserted-by":"crossref","unstructured":"Li G, Lv CA, Tian L, et al. A retrospective study of alendronate for the treatment of ankylosing spondylitis. Medicine. 2018;97:e10738.","DOI":"10.1097\/MD.0000000000010738"},{"issue":"6","key":"10.1016\/j.jocn.2021.08.016_b0105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/03009742.2015.1038300","article-title":"Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial","volume":"44","author":"Mok","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.jocn.2021.08.016_b0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/ket321","article-title":"Bisphosphonates vs infliximab in ankylosing spondylitis treatment","volume":"53","author":"Viapiana","year":"2014","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.jocn.2021.08.016_b0115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s001980170084","article-title":"Changes in Bone Density in Patients with Ankylosing Spondylitis: A Two-Year Follow-Up Study","volume":"12","author":"Maillefert","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocn.2021.08.016_b0120","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/ard.2004.022871","article-title":"An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover","volume":"64","author":"Cairns","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jocn.2021.08.016_b0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocn.2021.08.016_b0130","doi-asserted-by":"crossref","unstructured":"Planas J, Trilla E, Ravent\u00f3s C, et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int. 2009;104:1637-40.","DOI":"10.1111\/j.1464-410X.2009.08622.x"},{"key":"10.1016\/j.jocn.2021.08.016_b0135","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guideline 6. Rating the quality of evidence\u2013imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821004355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821004355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:27:19Z","timestamp":1760822839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821004355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"alternative-id":["S0967586821004355"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.08.016","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of bisphosphonates on ankylosing spondylitis: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}